de Souza Fernando Henrique Carlos, Barros Thiago Bitar Morais, Levy-Neto Mauricio, Shinjo Samuel Katsuyuki
Serviço de Reumatologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC/FMUSP), São Paulo.
Acta Reumatol Port. 2012 Apr-Jun;37(2):180-3.
The application of immunobiologics for the rheumatoid arthritis treatment may present as a rare complication the development of inflammatory myopathy. Until this moment, there have been described in literature only seven cases of inhibitors of tumor necrosis factor induced-myositis. In this paper, we report the case of the patient with 39 years-old with eight years of arthritis rheumatoid and that due to refractory to various immunosuppressive drugs, the adalimumab was introduced, and evolved to dermatomyositis status.
免疫生物制剂在类风湿关节炎治疗中的应用可能会引发一种罕见的并发症，即炎性肌病。截至目前，文献中仅报道了7例肿瘤坏死因子抑制剂诱发的肌炎病例。在本文中，我们报告了一名39岁的类风湿关节炎患者，该患者患关节炎已有8年，因对多种免疫抑制药物治疗无效，开始使用阿达木单抗治疗，随后发展为皮肌炎。
